Skip to Content

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

In this MEDtalk Dr. Jeff Sharman from Hematology Research for U.S. Oncology presents the six-year follow-up data from the Elevate-TN study. The study explores the comparative effectiveness and safety profiles of acalabrutinib with or without obinutuzumab against standard chemo-immunotherapy in the frontline treatment of Chronic Lymphocytic Leukemia (CLL), including the impact of adding obinutuzumab on progression-free survival and its implications for specific molecular subgroups.

Jeff P. Sharman

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top